Deal Watch: Medivation Enters Confidential Talks With Suitors, Including Sanofi
Bristol acquires Swedish biotech Cormorant to bolster its immuno-oncology franchise. Moderna quickly follows up its cancer partnership with another with Vertex to use mRNA approaches to treat cystic fibrosis.
You may also be interested in...
Deals for technology platforms allow more of a multiple-shots-on-goal approach as opposed to taking a risk with one or two candidates.
The JVs will develop and commercialize therapeutics for multiple cancer types and autoimmune disorders in China. Novocure partners its Tumor Treating Fields technology with Zai Lab, while Fate and ONO will collaborate on off-the-shelf CAR-T therapies.
Stakeholders are eager for details on the Takeda/Shire merger and on what Trump said to Pfizer CEO Ian Read to cause the recent about-face on price increases. Other key topics will be status updates on Teva's Copaxone franchise and on Novo Nordisk's oral semaglutide.